<div id="readability-page-1"><p>Prudential Financial Inc. lowered its holdings in shares of  Haemonetics Corporation (NYSE:HAE - Free Report) by 73.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 7,689 shares of the medical instruments supplier's stock after selling 21,398 shares during the quarter. Prudential Financial Inc.'s holdings in Haemonetics were worth $574,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><p>Other large investors have also recently made changes to their positions in the company. Quarry LP boosted its stake in  Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 192 shares during the period.  GAMMA Investing LLC lifted its holdings in shares of  Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier's stock worth $33,000 after acquiring an additional 165 shares during the last quarter.  UMB Bank n.a. boosted its stake in shares of  Haemonetics by 91.7% during the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier's stock worth $50,000 after purchasing an additional 320 shares during the period.  Parkside Financial Bank &amp; Trust grew its holdings in  Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank &amp; Trust now owns 1,461 shares of the medical instruments supplier's stock valued at $109,000 after purchasing an additional 152 shares during the last quarter.  Finally, Nisa Investment Advisors LLC grew its holdings in  Haemonetics by 85.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,470 shares of the medical instruments supplier's stock valued at $110,000 after purchasing an additional 677 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>A number of research analysts have recently commented on HAE shares. BTIG Research  restated a &#34;buy&#34; rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Citigroup lowered their price objective on shares of Haemonetics from $78.00 to $64.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, October 7th. Weiss Ratings  restated a &#34;hold (c-)&#34; rating on shares of Haemonetics in a research note on Monday. Raymond James Financial  reaffirmed an &#34;outperform&#34; rating and set a $90.00 price target on shares of Haemonetics in a research note on Friday, November 14th. Finally, Wall Street Zen raised Haemonetics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday. One equities research analyst  has rated the stock with a Strong Buy rating, eight have assigned  a Buy rating, two have given a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $79.70.</p><p><b>Get Our Latest Report on Haemonetics</b></p><h2>Haemonetics Stock Up 0.7%</h2><p>Shares of HAE stock opened at $83.83 on Wednesday. The stock's fifty day moving average price is $63.24 and its 200 day moving average price is $64.03. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $85.48. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.49 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. </p><p>Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. During the same quarter in the previous year, the firm earned $1.12 EPS. Haemonetics's revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.  On average, research analysts expect that  Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year. </p><h2>Haemonetics Company Profile</h2> (Free Report)<p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Haemonetics</li><li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>How to Invest in Blue Chip Stocks</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>What is the NASDAQ Stock Exchange?</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><strong>Want to see what other hedge funds are holding HAE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2><p>Before you consider Haemonetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Prudential Financial Inc. reduced its holdings in Haemonetics Corporation by 73.6% in Q2, owning 7,689 shares worth $574,000. Other investors adjusted their positions, with Quarry LP, GAMMA Investing LLC, UMB Bank n.a., Parkside Financial Bank & Trust, and Nisa Investment Advisors LLC increasing their stakes. Analysts have mixed ratings on Haemonetics, with a consensus target price of $79.70. Haemonetics reported Q2 earnings of $1.27 per share, beating estimates, but revenue decreased by 5.3% year-over-year.</p>

Prudential Financial Inc. Decreases Stake in Haemonetics Corporation $HAE